๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Neuropharmacology of venlafaxine

โœ Scribed by Patrick H. Roseboom; Ned H. Kalin


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
91 KB
Volume
12
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

โœฆ Synopsis


Venlafaxine (Effexor) is an effective antidepressant and has also been approved for the treatment of generalized anxiety disorder. Venlafaxine was initially characterized as an inhibitor of both serotonin (5HT) and norepinephrine (NE) uptake and was therefore termed a "dual uptake inhibitor." This chapter reviews data from both in vitro and in vivo studies regarding its effects on 5HT and NE neurotransmission. In addition, the effects of venlafaxine on other systems that may play a role in its therapeutic efficacy effects are described. The data indicate that venlafaxine is a relatively weak inhibitor of NE transport in vitro. In vivo studies indicate that venlafaxine selectively inhibits 5HT uptake at low therapeutic doses and inhibits both 5HT and NE uptake at higher therapeutic doses. This chapter concludes with a discussion of the effects of venlafaxine on various aspects of physiology.


๐Ÿ“œ SIMILAR VOLUMES


Behavioral neuropharmacology
โœ Zimmerman, Andrew W. ;Jinnah, H. A. ;Lockhart, Paula J. ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 132 KB

Having an appreciation for neurobiologic complexity in developmentally disabled children and adolescents with behavior disorders improves our ability to treat them with drugs that have become increasingly specific in their effects. Reductionist analysis of phenotypic and genotypic disorders improves

Antidepressant efficacy of venlafaxine
โœ Robert N. Golden; Linda Nicholas ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 58 KB ๐Ÿ‘ 1 views

Venlafaxine is a unique antidepressant medication with well documented efficacy and safety in the acute treatment of major depressive disorder. Reports suggest that it may also be effective in the treatment of dysthymic disorder and bipolar II depression, but the available data for these conditions